3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
3
Phase NA
1
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
13
Leukemia
4
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Congenital Abnormalities
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Biphenotypic, Acute
2
Thrombocythemia, Essential
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Burkitt Lymphoma
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
4
blinatumomab
3
Azacitidine
3
venetoclax
2
tetrathiomolybdate
1
tagraxofusp
1
siremadlin
1
sabatolimab
1
posaconazole
1
pembrolizumab
1
midostaurin
1
fludarabine phosphate
1
fludarabine
1
daratumumab
1
avelumab
1
aflutinib
1
Whole-Body Irradiation
1
Sirolimus
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Midazolam
1
Melphalan
1
Injections
1
Idarubicin
1
Daunorubicin
1
Cytarabine
1
Celecoxib
1
Capecitabine
1
Biological Assay
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm, Residual
×
Daunorubicin
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn